On Dec. 23, 2014, Juno Therapeutics announced the closing of its initial public offering of 12.7 million shares of common stock at a price to the public of $24.00 per share for net proceeds of $264 million. Juno Theraputics was launched in 2013 by the Fred Hutchinson Cancer Research Center and Memorial Sloan-Kettering Cancer Center, along with pediatric partner Seattle Children’s Research Institute.

In 2018, Juno Therapeutics was acquired by New Jersey-based Celgene for $9 billion, or $87 per share. A year later, Celgene was acquired by Bristol-Myers Squibb.